NAD+ Research Literature

Nicotinamide adenine dinucleotide — NAD+ — was discovered over 100 years ago as an electron carrier for metabolic enzymes. But in the last decade, it has become the single most studied molecule in aging research, with a surge of published literature connecting NAD+ levels to nearly every major age-related process in the body.

The numbers are staggering: over 500 enzymatic reactions require NAD+ to function. It fuels DNA repair, drives mitochondrial energy production, regulates circadian rhythms, controls inflammatory responses, and activates sirtuins — the family of enzymes often called the "longevity genes." When researchers say NAD+ is involved in "almost all biological processes," they are not exaggerating.

A study published in Rejuvenation Research measured NAD+ levels in blood plasma from healthy human subjects ranging from 20 to 87 years old using liquid chromatography coupled to tandem mass spectrometry. The findings were definitive: NAD+ levels decline significantly with age. NADP+, NAAD, and other critical metabolites also declined, confirming that the entire NAD+ metabolome deteriorates during normal aging.

This is not a subtle shift. The decline has been documented across multiple tissues and organ systems, affecting everything from liver function to immune response to brain health. Published reviews describe it as one of the most consistent molecular signatures of aging identified to date.

The preclinical evidence for NAD+ restoration is extensive. In published mouse studies, supplementing with NAD+ precursors has improved gluconeogenesis in the liver, insulin secretion in the pancreas, immune functioning in lymphoid tissues, cardioprotection in the heart, and sensory and motor function in the brain. Multiple studies have documented lifespan extension in model organisms when NAD+ levels are maintained.

A 2018 review by Rajman and colleagues published in Cell Metabolism provided a comprehensive synthesis of NAD+ biology in aging, documenting the breadth of systems affected by NAD+ decline and the consistent benefits of restoration across preclinical models.

The translation from preclinical to human research has accelerated rapidly. A 2025 review published in Nature Aging by Zhang, Fang, and colleagues documented the emerging clinical landscape — including trials investigating NAD+ precursors for Parkinson's disease, cognitive decline, cardiovascular function, and metabolic health.

The NADPARK study, a randomized Phase 1 trial published in Cell Metabolism in 2022 by Brakedal and colleagues, supplemented Parkinson's disease patients with nicotinamide riboside (an NAD+ precursor). Researchers documented increased cerebral NAD+ levels and observed changes in clinical and neuroimaging outcomes, providing some of the first direct evidence that NAD+ supplementation can alter brain metabolism in humans.

A randomized placebo-controlled trial by Orr and colleagues published in GeroScience in 2024 examined nicotinamide riboside supplementation in older adults with mild cognitive impairment. The study documented measurable changes in NAD+ metabolites and explored associations with cognitive outcomes.

A separate Phase 2 pilot study by Martens and colleagues, presented at the Alzheimer's Association International Conference in 2025, examined nicotinamide riboside supplementation specifically in older adults with amnestic mild cognitive impairment — the type most likely to progress to Alzheimer's disease.

One of the most compelling areas of NAD+ research involves DNA repair. NAD+ is a required substrate for PARP enzymes — the molecular machinery that detects and repairs DNA damage. When NAD+ levels drop, PARP function is compromised, and DNA damage accumulates.

A 2025 review published in Aging Cell examined this connection in rare diseases characterized by premature aging and defective DNA repair. The researchers documented that NAD+ supplementation improved DNA repair capacity and mitochondrial function in model systems mimicking these conditions. The findings suggest that NAD+ depletion is not just a marker of aging — it may be a mechanistic driver.

NAD+ sits at the center of mitochondrial energy production. Every cell in the body depends on mitochondria to convert nutrients into usable energy, and NAD+ is required at multiple steps in that process. As NAD+ declines, mitochondrial function degrades — producing less energy, more oxidative stress, and accelerating cellular aging.

Published research has shown that restoring NAD+ levels can reinstate mitochondrial function in aged cells. This connection between NAD+, mitochondrial health, and aging has been documented across dozens of published studies and multiple tissue types.

NAD+ occupies a unique position in the research landscape because it is not a single-pathway compound — it is a fundamental metabolic cofactor that affects hundreds of processes simultaneously. BPC-157 and TB-500 target tissue repair specifically. GLP-1 and GLP-3RT target metabolic pathways specifically. NAD+ affects the underlying cellular machinery that all of these systems depend on. That is why some researchers describe it as the most upstream intervention point in aging research.